Viemed Healthcare US ( (VMD) ) has released its Q1 earnings. Here is a breakdown of the information Viemed Healthcare US presented to its investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Viemed Healthcare, Inc. is a leading provider of in-home respiratory care and medical equipment services across the United States, focusing on non-invasive ventilators, sleep therapy, and other complementary healthcare services.
In its first quarter of 2025, Viemed Healthcare reported a significant increase in financial performance, with net revenues reaching $59.1 million, marking a 17% increase compared to the same period in 2024. The company also announced an acquisition agreement set to enhance its market position.
Key financial metrics for the quarter include a 64% increase in net income, totaling $2.6 million, and a 26% rise in Adjusted EBITDA, reaching $12.8 million. The company also reported a strong cash position with $10.2 million in cash and $55 million available under existing credit facilities. Additionally, Viemed saw growth in its patient base, particularly in PAP therapy, which increased by 46% year-over-year.
Strategically, Viemed has agreed to acquire Lehan’s Medical Equipment for approximately $26 million, a move expected to bolster its respiratory and women’s health offerings. This acquisition, however, is not yet reflected in the company’s 2025 financial guidance, which has been slightly adjusted upwards.
Looking ahead, Viemed’s management remains optimistic, citing improvements in sales organization and technology investments as key drivers for future growth. The company is well-positioned to continue its expansion and capitalize on opportunities in the respiratory care market, despite broader economic uncertainties.